ArticleTransplantation direct2025
The Accuracy of Blood Nucleic Acid Testing to Predict BK Polyomavirus Nephropathy Varies by Clinical Context.
Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kidney Transplant Recipients: Viral Infections and Malignancies.Pathogens (Basel, Switzerland) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: BK polyomavirus (BKPyV) reactivation causes a destructive allograft nephropathy (BKVAN) with limited treatment options. Quantitative nucleic acid testing (QNAT) of BKPyV-DNA in blood within screening programs monitors for viral reactivation but has imprecise real-world authentication. Methods: This prospective, single-gate, single-center, population-based cohort study evaluated the test performances of QNAT (the index test) against biopsy-proven BKVAN, verified by universal Simian virus 40 T antigen (SV40T) immunohistochemistry (the optimal reference test), in 5339 consecutive kidney transplant samples. Results: BKVAN occurred in 205 tissue samples (3.8%) obtained from 1542 recipients (6.9%); classified as polyomavirus nephropathy class 1 in 26.3%, class 2 in 67.8%, and late class 3 in 5.9%. Contemporaneous QNAT Conclusions: Test performance of QNAT in transplant recipients varies markedly according to clinical context. A negative QNAT in surveillance programs reliably rules out BKVAN. However, although positive results confirm BKV reactivation, QNAT levels could not accurately distinguish tissue-invasive infection at any threshold value.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.